Drug Database
Back to search

Belgium· BE-AMP-SAM662568-00

Emblaveo 1.5 g - 0.5 g

A aztreonam und beta-lactamase-inhibitor product containing aztreonam, registered in Belgium by Pfizer Europe MA. The same ATC class is registered in 7 of our 19 countries.

ATC J01DF51

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedEmblaveo 1.5 g - 0.5 gATCJ01DF51REGISTER NO.BE-AMP-SAM662568-00PACKS LISTED0CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about aztreonamAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Aztreonam und beta-lactamase-inhibitor is registered in 7 of 19 countries.

Countries holding a registration under ATC J01DF51 (aztreonam und beta-lactamase-inhibitor), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 4 of them publish a price we can compare per daily dose
Search aztreonam und beta-lactamase-inhibitor products by name

Aztreonam und beta-lactamase-inhibitor · ATC J01DF51

7 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Aztreonam
Manufacturer
Pfizer Europe MA
Country
Belgium (BE)
ATC code
J01DF51
ATC class
Aztreonam und Beta-Lactamase-Inhibitor
Defined daily dose
6 g, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Aztreonam und beta-lactamase-inhibitor in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aztreonam und beta-lactamase-inhibitor products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Azactam
  • Spain · Azactam
  • Finland · Azactam
  • France · Azactam
  • United Kingdom (Northern Ireland) · Aztreonam Kent Pharma Uk, Aztreonam Kent Pharma Uk Ltd
  • Ireland · Azactam
  • Iceland · Cayston
  • Liechtenstein · Cayston
  • Luxembourg · Azactam
  • Norway · Azactam, Cayston
  • Portugal · Azactam
  • Romania · Azactam
  • Sweden · Azactam

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5a3dd236-0c64-4fae-9bf9-de95cee6fd69
GET /v1/drugs/5a3dd236-0c64-4fae-9bf9-de95cee6fd69?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder for concentrate for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Emblaveo 1.5 g - 0.5 g",
  "name_fr": "Emblaveo 1.5 g - 0.5 g",
  "name_nl": "Emblaveo 1.5 g - 0.5 g",
  "amp_code": "SAM662568-00",
  "strengths": [
    "1.5000",
    "1.5000",
    "0.5000",
    "0.5000",
    "44.6000"
  ],
  "pack_count": 1,
  "substances": [
    "Aztreonam",
    "Avibactam Sodium",
    "Avibactam",
    "Sodium"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Aztreonam and Beta-lactamase Inhibitor",
  "authorisation_numbers": [
    "EU/1/24/1808/001"
  ]
}
API referenceMCP serverPlans

See everything about aztreonam und beta-lactamase-inhibitor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console